Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2026)

Xeris Biopharma Holdings has reported EBIT Margin for 7 years, with the latest figure at 9.52% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 1466.0% year-over-year to 9.52%; the trailing twelve-month figure through Mar 2026 stood at 11.4% (up 2151.0% YoY), and the FY2025 full-year result was 8.53%, up 2510.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 9.52%, down from 19.55% in the prior quarter.
• The five-year high for EBIT Margin was 19.55% in Q4 2025, with the low at 131.72% in Q1 2022.
• Historically, EBIT Margin has averaged 27.27% across 5 years, with a median of 22.17% in 2023.
• Annual changes were most pronounced in 2022 — EBIT Margin surged 21480 bps — and 2024, when it tumbled 1359 bps.
• Xeris Biopharma Holdings' EBIT Margin stood at 45.77% in 2022, then soared by 52 bps to 22.17% in 2023, then jumped by 113 bps to 2.79% in 2024, then jumped by 600 bps to 19.55% in 2025, then plunged by 51 bps to 9.52% in 2026.
• The last three EBIT Margin figures came in at 9.52% (Q1 2026), 19.55% (Q4 2025), and 9.05% (Q3 2025), per Business Quant data.